NYSE:ADCT

Adc Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy ADCT

*Your capital is at risk

$3.08

-0.0900 (-2.84%)

At Close: Jun 03, 2026

Adc Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 72.73. In total, the insiders bought 86M and sold 8.32M ADCT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	72.73
● Buy	86M shares
● Sell	8.32M shares
57% Buy Activity Moderate Positive Correlation
Sell Signal Low Confidence Apr 02, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 72.73. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 11, 2024 Buy	Common Shares, par value CHF 0.08 per share P-Purchase	Redmile Group, Llc 10 Percent Owner	10% Owner	50 000 Value: $114.0K
Dec 11, 2024 Buy	Common Shares, par value CHF 0.08 per share P-Purchase	Redmile Group, Llc 10 Percent Owner	10% Owner	50 000 Value: $114.0K
Dec 11, 2024 Buy	Common Shares, par value CHF 0.08 per share P-Purchase	Redmile Group, Llc 10 Percent Owner	10% Owner	50 000 Value: $190.5K
Dec 11, 2024 Buy	Common Shares, par value CHF 0.08 per share P-Purchase	Redmile Group, Llc 10 Percent Owner	10% Owner	50 000 Value: $114.0K
Dec 11, 2024 Buy	Common Shares, par value CHF 0.08 per share P-Purchase	Redmile Group, Llc 10 Percent Owner	10% Owner	50 000 Value: $190.5K
Dec 06, 2024 Sell	Common Shares F-InKind	Zaki Mohamed Chief Medical Officer	Officer	37 112 Value: $116.2K
Dec 06, 2024 Sell	Common Shares F-InKind	Kallebo Lisa Michelle Chief Accounting Officer	Officer	6 503 Value: $20.4K
Dec 06, 2024 Sell	Common Shares F-InKind	Carmona Jose Chief Financial Officer	C-Suite Officer	48 108 Value: $150.6K
Dec 06, 2024 Sell	Common Shares F-InKind	Graham Peter J Chief Legal Officer	Officer	41 458 Value: $129.8K
Dec 06, 2024 Sell	Common Shares F-InKind	Mallik Ameet Chief Executive Officer	CEO / President	238 343 Value: $746.0K
Dec 06, 2024 Sell	Common Shares F-InKind	Mallik Ameet Chief Executive Officer	CEO / President	238 343 Value: $746.0K
Dec 06, 2024 Sell	Common Shares F-InKind	Graham Peter J Chief Legal Officer	Officer	41 458 Value: $129.8K
Dec 06, 2024 Sell	Common Shares F-InKind	Carmona Jose Chief Financial Officer	C-Suite Officer	48 108 Value: $150.6K
Dec 06, 2024 Sell	Common Shares F-InKind	Kallebo Lisa Michelle Chief Accounting Officer	Officer	6 503 Value: $20.4K
Dec 06, 2024 Sell	Common Shares F-InKind	Zaki Mohamed Chief Medical Officer	Officer	37 112 Value: $116.2K
Dec 04, 2024 Sell	Common Shares, par value CHF 0.08 per share J-Other	Redmile Group, Llc 10 Percent Owner	10% Owner	50 672 Value: $104.9K
Dec 04, 2024 Buy	Common Shares, par value CHF 0.08 per share J-Other	Redmile Group, Llc 10 Percent Owner	10% Owner	50 672 Value: $104.9K
Jan 02, 2024 Buy	Common Shares	Squarer Ron Director	Director	0 Value: $0
Jan 02, 2024 Buy	Stock Options (Right to Buy)	Squarer Ron Director	Director	159 026 Value: $2.98M
Jan 02, 2024 Buy	Stock Options (Right to Buy)	Squarer Ron Director	Director	27 412 Value: $786.7K
Jan 02, 2024 Buy	Stock Options (Right to Buy)	Squarer Ron Director	Director	29 836 Value: $417.7K
Jan 02, 2024 Buy	Stock Options (Right to Buy)	Squarer Ron Director	Director	27 412 Value: $786.7K
Jan 02, 2024 Buy	Stock Options (Right to Buy)	Squarer Ron Director	Director	159 026 Value: $2.98M
Jan 02, 2024 Buy	Common Shares	Squarer Ron Director	Director	0 Value: $0
Jan 02, 2024 Buy	Stock Options (Right to Buy)	Squarer Ron Director	Director	29 836 Value: $417.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ADC THERAPEUTICS LTD

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second...

Read Full Profile Here